Your browser doesn't support javascript.
loading
"Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)".
Rasmussen, Bengt; Göhring, Gudrun; Bernard, Elsa; Nilsson, Lars; Tobiasson, Magnus; Jädersten, Martin; Garelius, Hege; Dybedal, Ingunn; Grønbaek, Kirsten; Ejerblad, Elisabeth; Lorenz, Fryderyk; Flogegård, Max; Marcher, Claus Werenberg; Öster Fernström, Annette; Cavelier, Lucia; Papaemmanuil, Elli; Ebeling, Freja; Kittang, Astrid Olsnes; Nørgaard, Jan Maxwell; Saft, Leonie; Möllgård, Lars; Hellström-Lindberg, Eva.
Afiliación
  • Rasmussen B; School of Medical Sciences, Örebro University, Örebro, Sweden.
  • Göhring G; Department of Human Genetics, Hannover Medical School, Hannover, Germany.
  • Bernard E; Computational Oncology Service, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Nilsson L; Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden.
  • Tobiasson M; Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Jädersten M; Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Garelius H; Section for Hematology and Coagulation, Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Dybedal I; Department of Hematology, Oslo University Hospital, Oslo, Norway.
  • Grønbaek K; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Ejerblad E; Department of Medical Science, Section of Hematology, Uppsala University, Uppsala, Sweden.
  • Lorenz F; Department of Medical Biosciences, Umeå University, Umeå, Sweden.
  • Flogegård M; Department of Internal Medicine, Falun General Hospital, Falun, Sweden.
  • Marcher CW; Department of Hematology, Odense University Hospital, Odense, Denmark.
  • Öster Fernström A; Department of Medicine Huddinge, Center for Hematology and Regenerative Medicine (HERM), Karolinska Institutet, Stockholm, Sweden.
  • Cavelier L; Clinical Genomics Facility, Uppsala, Science for Life Laboratory IGP, Rudbeck Laboratory, Uppsala University and Clinical Genetics, Uppsala University Hospital, Uppsala, Sweden.
  • Papaemmanuil E; Computational Oncology Service, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Ebeling F; Department of Medicine, Division of Hematology, Helsinki University Central Hospital, Helsinki, Finland.
  • Kittang AO; Division for Hematology, Department of Medicine, Haukeland University Hospital, Bergen, Norway.
  • Nørgaard JM; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark.
  • Saft L; Department of Clinical Pathology, Division of Hematopathology, Karolinska University Hospital and Institute, Solna, Stockholm, Sweden.
  • Möllgård L; Section for Hematology and Coagulation, Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Hellström-Lindberg E; Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. eva.hellstrom-lindberg@ki.se.
Leukemia ; 36(5): 1436-1439, 2022 05.
Article en En | MEDLINE | ID: mdl-35277655

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndromes Mielodisplásicos / Leucemia Mieloide Aguda Tipo de estudio: Clinical_trials / Etiology_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Suecia Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndromes Mielodisplásicos / Leucemia Mieloide Aguda Tipo de estudio: Clinical_trials / Etiology_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Suecia Pais de publicación: Reino Unido